Scinai Immunotherapeutics Ltd. Sponsored ADR SCNI
1.55
(0.31)
(16.67%)
as of 25 Sep
- Market cap
- $1.2M
- P/E
- 0.0×
Follow SCNI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
P/Operating CF |
(0.90) | (0.54) | — | — | — | — | — | — | — | — |
P/B ratio |
0.56 | 0.65 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
0.56 | 0.65 | — | — | — | — | — | — | — | — |
EV/Sales |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
EV/Operating CF |
(0.02) | (0.24) | — | — | — | — | — | — | — | — |
EV/FCF |
(0.02) | (0.23) | — | — | — | — | — | — | — | — |
Quick Ratio |
1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.04 |
Current Ratio |
1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.04 |
Net Debt/EBITDA |
0.25 | 0.26 | (1.56) | (0.60) | (0.95) | 5.84 | (0.68) | (0.24) | 3.07 | 2.25 |
Debt/Assets |
2.53% | 1.93% | 110.85% | 75.60% | 85.57% | 116.88% | 107.54% | 89.16% | 0.00% | 0.00% |
Debt/Equity |
0.04 | 0.03 | (4.24) | (11.63) | 27.91 | (4.56) | (1.91) | (3.02) | 0.00 | 0.00 |
Asset Turnover |
0.10 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.73 | (1.32) | 1.44 | 1.25 | 0.90 | 16.28 | 0.71 | 0.65 | 0.29 | 1.05 |
Capex/Depreciation |
(0.02) | (0.01) | (1.24) | (1.49) | (0.30) | (2.45) | (4.52) | (91.23) | (10.24) | (0.03) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (243.39%) | (4,379.91%) | 205.40% | 1,489.97% | 461.27% | 11.86% | 232.74% | (592.81%) | (87.09%) | (31.31%) | |
| (66.26%) | 31.02% | (29.19%) | (19.61%) | (33.00%) | (5.41%) | (102.37%) | (90.37%) | (63.49%) | (25.94%) | |
ROIC |
(71.57%) | (66.31%) | (61.97%) | (154.00%) | (62.41%) | 10.79% | 0.00% | 0.00% | 0.00% | (2,545.23%) |
Return on Tangible Assets |
(100.54%) | 49.07% | (44.85%) | (24.90%) | (29.53%) | 31.93% | (122.49%) | (105.32%) | (46.74%) | (35.05%) |
Average Days of Receivables |
67.65 | 164.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
180.70% | 840.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
192.30% | 383.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
23.11% | 103.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(1.07) | (0.23) | — | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Earnings Yield |
(32,642.36%) | (6,726.00%) | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(700.21%) | (352.76%) | — | — | — | — | — | — | — | — |
Revenue per Share |
5.61 | 8.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(25.83) | (78.60) | (239.95) | (384.39) | (526.67) | (2,032.61) | (2,719.15) | (2,347.85) | (579.80) | (738.53) |
Capex per Share |
(0.10) | (0.15) | (16.29) | (44.23) | (9.86) | (167.30) | (262.20) | (968.46) | (260.00) | (1.47) |
Free Cash Flow per Share |
(25.93) | (78.75) | (256.24) | (428.62) | (536.52) | (2,199.91) | (2,981.34) | (3,316.31) | (839.80) | (740.00) |
Cash per Share |
7.76 | 25.99 | 128.13 | 752.12 | 1,242.34 | 263.96 | 2,557.07 | 3,114.77 | 4,117.80 | 1,937.06 |
Shareholders Equity per Share |
34.70 | 123.78 | (116.85) | (93.12) | 69.65 | (409.01) | (2,295.49) | (1,281.23) | 3,245.00 | 1,959.41 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
34.70 | 123.78 | (116.85) | (93.12) | 69.65 | (409.01) | (2,295.49) | (1,281.23) | 3,245.00 | 1,959.41 |
Free Cash Flow |
(6.05) | (6.35) | (10.02) | (8.10) | (7.56) | (24.42) | (24.45) | (21.56) | (4.20) | (2.52) |
Working Capital |
0.47 | 0.59 | 3.67 | 12.03 | 15.40 | (16.66) | 15.67 | 14.69 | 19.74 | 6.44 |
Capital Expenditures |
(0.02) | (0.01) | (0.64) | (0.84) | (0.14) | (1.86) | (2.15) | (6.29) | (1.30) | 0.00 |
Net Current Asset Value |
(1.47) | (1.08) | (16.59) | (14.46) | (13.21) | (18.94) | (31.16) | (16.06) | 14.38 | 5.63 |
EV/EBIT |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Capex to Sales |
0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(633.64%) | 728.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.18 | 0.18 | 0.05 | 0.05 | 0.04 | 0.06 | 0.05 | 0.01 | 0.08 | 0.43 |
Cash ROIC |
(135.42%) | (125.88%) | (102.01%) | (56.23%) | (43.15%) | (182.82%) | (84.95%) | (61.46%) | (12.19%) | (21.78%) |
Accounts Receivable Turnover |
4.86 | 1.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
10.12 | 2.72 | 0.00 | 0.65 | 0.95 | 0.26 | 0.09 | 0.02 | 0.13 | 0.78 |
Inventory Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
37.49 | 110.86 | 0.00 | 466.85 | 487.68 | 299.15 | 3,902.98 | 27,912.66 | 5,300.77 | 400.31 |
Days of Inventory on Hand |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.27 | 0.37 | 0.30 | 0.24 | 0.35 | 0.28 | 0.22 | 0.69 | 0.67 | 0.29 |
Average Payables |
0.39 | 0.46 | 0.63 | 0.86 | 0.79 | 2.76 | 5.23 | 3.66 | 0.99 | 0.21 |
Average Assets |
12.54 | 15.46 | 22.27 | 29.55 | 24.87 | 25.60 | 30.87 | 25.90 | 15.70 | 9.21 |
Average Common Equity |
3.41 | (0.11) | (3.16) | (0.39) | (1.78) | (11.68) | (13.58) | 3.95 | 11.44 | 7.63 |
Columns are period end dates